Share on StockTwits

Shares of Verastem (NASDAQ:VSTM) have received an average recommendation of “Buy” from the ten ratings firms that are currently covering the stock, Analyst Ratings Net reports. Nine investment analysts have rated the stock with a buy recommendation, The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $21.40.

A number of analysts have recently weighed in on VSTM shares. Analysts at Deutsche Bank initiated coverage on shares of Verastem in a research note on Tuesday. They set a “buy” rating and a $14.00 price target on the stock. Analysts at Mizuho initiated coverage on shares of Verastem in a research note on Monday, February 10th. They set a “buy” rating and a $21.00 price target on the stock.

Shares of Verastem (NASDAQ:VSTM) traded up 1.86% on Tuesday, hitting $8.20. The stock had a trading volume of 70,070 shares. Verastem has a one year low of $7.47 and a one year high of $18.82. The stock’s 50-day moving average is $9.96 and its 200-day moving average is $11.67. The company’s market cap is $211.7 million.

Verastem (NASDAQ:VSTM) last announced its earnings results on Thursday, March 6th. The company reported ($0.45) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.47) by $0.02. On average, analysts predict that Verastem will post $-1.79 earnings per share for the current fiscal year.

Verastem, Inc is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.